April 20, 2024Open Access

A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice

JLJin LiShanghai Cancer Institute ZWZhi‐Qiang WangNanjing University of Chinese Medicine HZHaijun ZhongShanghai Jiao Tong University

Key Points

Key points are not available for this paper at this time.

Abstract

Fruquintinib is approved in China for patients with metastatic colorectal cancer (CRC) who progressed after 2 lines of chemotherapy. This postmarketing study was conducted to evaluate the safety of fruquintinib in the Chinese population, including previously treated patients with advanced CRC and other solid tumors.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Cite This Study

Li et al. (Sat,) studied this question.

synapsesocial.com/papers/68e6e4f3b6db64358765ffef https://doi.org/https://doi.org/10.1093/oncolo/oyae073

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: